Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Special Article
March 12, 2001

Environmental and Drug Effects on Patients With Pacemakers and Implantable Cardioverter/DefibrillatorsA Practical Guide to Patient Treatment

Nora Goldschlager, MD; Andrew Epstein, MD; Paul Friedman, MD; et al Eli Gang, MD; Ryszard Krol, MD, PhD; Brian Olshansky, MD; for the North American Society of Pacing and Electrophysiology (NASPE) Practice Guideline Committee
Author Affiliations

Dr Epstein has been an investigator for Guidant Corp, Medtronic Inc, St Jude Medical, and Biotronik GmbH & Co. He also chairs the Events Committee for Guidant Corp.


Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001

Arch Intern Med. 2001;161(5):649-655. doi:10.1001/archinte.161.5.649

The potential for interaction between pacemakers and implantable cardioverter/defibrillators (ICDs) and the medical and nonmedical environment, and between these devices and certain cardioactive drugs, has been recognized for years. Whereas a number of experimental and clinical studies have been performed to define some of these interactions, in many instances data are sparse and anecdotal clinical experiences form the basis for decision making and recommendations. Nevertheless, given the proliferation of rhythm-management devices in use in the population today, practitioners may find a guide to management of these patients helpful. This management guideline is therefore offered not as an extensive, literature-based review, but as a framework on which to understand specific types of problems that may be encountered in the daily lives of patients who have such implanted devices.

First Page Preview View Large
First page PDF preview
First page PDF preview